Treating Social Cognition With Theta Burst Stimulation; a Pilot Sudy

NCT ID: NCT02440867

Last Updated: 2017-07-21

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-05-31
• Study Completion Date: 2018-12-31

Brief Summary

The purpose of the study is to test a new treatment of social cognition deficits in patients with schizophrenia or schizoaffective disorder by transcranial magnetic stimulation (theta-burst). The study will also identify clinical variables, cognitive and psychomotor most sensitive to treatment, to estimate the most sensitive treatment target, assess tolerance, to assess the impact of repetitive Transcranial Magnetic Stimulation (rTMS) on the brain a multimodal imaging study and compare the imaging variables (resting network, Diffusion Tensor Imaging, magnetic resonance spectroscopic imaging; MRSI) between patients before treatment and healthy subjects.

Detailed Description

The language understanding of other people is based on linguistic decoding mechanisms (phonological, semantic, syntactic ...) but also more on subtle mechanisms for the recognition of emotions and intentions. Interact with another one requires understanding its language but also to infer emotions and intentions. There are patients with schizophrenia suffering from social cognition disorders that impair social interactions; These patients often have difficulty in extracting the non-verbal emotional content of language and have difficulty inferring the thoughts and intentions of others. Recently, we have suggested a link between such deficits and the hypofunction of the medial prefrontal cortex.

Transcranial magnetic stimulation is a noninvasive neuromodulation technique that increases or decreases the focal cortical excitability depending on stimulation parameters. This technique is now commonly used as a therapeutic tool. It has been tried with some success in patients with schizophrenia in some indications:

• To reduce the auditory verbal hallucinations stimulating the temporal cortex
• More rarely, to reduce the negative symptoms stimulating the dorsolateral prefrontal cortex So far, the medial prefrontal cortex was not considered as a possible target as the scalp to cortex distance prevent from using conventional stimulation coils. Recently new coils have been developed that permit stimulation of deeper cortical regions.

We hypothesize that the use of transcranial magnetic stimulation with a theta burst intermittent protocol known to increase the cortical excitability and aiming the medial prefrontal cortex with a special antenna will improve social interaction capabilities of schizophrenic patients.

This ambitious and innovative assumption shall be first supported by a study of feasibility which is the subject of this trial.

Moreover, changes in the anatomical and functional connectivity, in brain metabolism and in cortical excitability will be observed after stimulation thanks to a multimodal imaging and the study of P50 wave.

In this pilot study, involving 20 patients, we plan to assess the social cognition deficits before and after 10 sessions of magnetic stimulation (2 sessions per day for 5 consecutive days) using a neuronavigation system and Magstim® stimulator. In order to assess the feasibility and specificity of the stimulation of medial prefrontal cortex (MPC), the effects of this treatment will be compared to the effects of the same treatment aiming the dorsolateral prefrontal cortex (DLPFC), also involved in aspects of negative symptoms of schizophrenia, and placebo effects induced by sham stimulation (using a sham coil). The recording of the P50 wave will be just before and after the 1st session and just after the last stimulation session. An MRI anatomical, functional and spectroscopic be performed before and 30 days after the treatment. A control group of twenty healthy subjects will perform the same MRI acquisitions.

Conditions

Social Cognition in Patients With Schizophrenia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Healthy subjects

Multimodal imaging data acquisitions Clinical data acquisitions

Group Type: NO_INTERVENTION

No interventions assigned to this group

TBS-MPC

• Intervention with active TBS aiming Medial Prefrontal Cortex in 6 patients with schizophrenia
• Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition
• Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition
• Continuous actimetry acquisition

Group Type: EXPERIMENTAL

Active TBS

Intervention Type: DEVICE

Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)

TBS-CPDLF

• Intervention with active TBS aiming Dorsolateral Prefrontal Cortex in 6 patients with schizophrenia
• Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition
• Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition
• Continuous actimetry acquisition

Group Type: ACTIVE_COMPARATOR

Active TBS

Intervention Type: DEVICE

Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)

TBS-Sham

• Intervention with Sham TBS in 8 patients with schizophrenia
• Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition
• Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition
• Continuous actimetry acquisition

Group Type: SHAM_COMPARATOR

Sham TBS

Intervention Type: DEVICE

Sham stimulation

Interventions

Active TBS

Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)

Intervention Type: DEVICE

Sham TBS

Sham stimulation

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• with a diagnosis of schizophrenia or schizoaffective disorder (DSM-IV MINI R)
• less than 20 years of disease duration
• Having signed a written informed consent
• LIS score > 15 or negative PANSS score > 15

Exclusion Criteria

• Any change in psychotropic drugs (antidepressants, antipsychotics or mood stabilizers) during the two months preceding the inclusion
• Pregnant or breastfeeding women
• Subjects with a neurological condition or with epilepsy
• Subjects with a counter-indication to MRI or Transcranial stimulation (electronic or metal implants)
• Subjects that refuse to wear earplugs during MRI

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University Hospital, Caen

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clément Nathou, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Caen

Locations

CHU de Caen - Centre Esquirol

Caen, , France

Site Status: RECRUITING

Countries

France

Central Contacts

Clement Nathou, MD

Role: CONTACT

nathou@chu-caen.fr

(0)231065018 ext. +33

Sonia Dollfus, MD, PhD

Role: CONTACT

dollfus@chu-caen.fr

(0)231065018 ext. +33

Facility Contacts

Clément Nathou, Dr.

Role: primary

nathou-c@chu-caen.fr

+33231065018

Other Identifiers

2014-A00839-38

Identifier Type: -

Identifier Source: org_study_id